Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via open-house model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 581 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pegfilgrastim (ATC-Code nach WHO: L03AA13)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No minimum volume or guaranteed revenue; actual demand depends on doctor prescribing and pharmacy dispensing behavior.

Potential early termination if exclusive agreements are concluded; the notice states this typically occurs 8–12 months...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive discount agreements for Pegfilgrastim (ATC L03AA13) under § 130a Abs. 8 SGB V.
  • Open-house model: continuous participation, no negotiations, no exclusivity.
Afficher le résumé complet

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via an open-house model by AOK PLUS, covering Saxony and Thuringia, Germany. No guaranteed volume; continuous participation; contract until 31 March 2028. Procurement law formally applies due to publication form, but the procedure is not a classic public procurement.

Risques

No minimum volume or guaranteed revenue; actual demand depends on doctor prescribing and pharmacy dispensing behavior.

Potential early termination if exclusive agreements are concluded; the notice states this typically occurs 8–12 months...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.

Eligibility

  • Must not be subject to mandatory or discretionary exclusion grounds under §§ 123, 124 GWB.
  • Must provide self-declarations: exclusion grounds and Russia sanctions (EU Regulation 833/2014).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not specified; award criteria field is a technicality and not binding per the notice.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via open-house model

Conclusion of non-exclusive discount agreements for the active ingredient Pegfilgrastim. Open to all qualified pharmaceutical entrepreneurs. No volume guarantees. Contract ends 31 March 2028 regardless of signing date. Subject to early termination if exclusive agreements are concluded.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Apr 2026 - Mar 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Not specified; award criteria field is a technicality and not binding per the notice.

Date limite

Deadline Mar 31, 2028

Détails de la procédure

Date de publication
19 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
122544-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30